Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.

ABSTRACT:

Background

Cancer immunotherapy has taken center stage in cancer treatment. However, the current immunotherapies only benefit a small proportion of patients with cancer, necessitating better understanding of the mechanisms of tumor immune evasion and improved cancer immunotherapy strategies. Regulatory T (Treg) cells play an important role in maintaining immune tolerance through inhibiting effector T-cell function. In the tumor microenvironment, Treg cells are used by tumor cells to counteract effector T cell-mediated tumor suppression. Targeting Treg cells may thus unleash the antitumor activity of effector T cells. While systemic depletion of Treg cells can cause excessive effector T-cell responses and subsequent autoimmune diseases, controlled targeting of Treg cells may benefit

SUBMITTER: Kalim KW 

PROVIDER: S-EPMC9703354 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature